The Study is Being Done to See if Taking the Drug Valganciclovir Can Prevent CMV Infection.
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
This study is being done in stem cell transplant recipients to see if taking the drug
valganciclovir can prevent or reduce serious cytomegalovirus (CMV) infections that can occur
100 days or later after transplant.
Phase:
Phase 3
Details
Lead Sponsor:
Mayo Clinic
Collaborators:
City of Hope National Medical Center Fred Hutchinson Cancer Research Center Roche Pharma AG University of Florida University of Michigan